Updated Phase 2 CAPTIVATE study results demonstrate
At 5 years, 67 percent of patients were progression-free, with overall survival at 96 percent for all treated patients 1 ...
Read moreAt 5 years, 67 percent of patients were progression-free, with overall survival at 96 percent for all treated patients 1 ...
Read moreCLEVELAND, April 23, 2024 (GLOBE NEWSWIRE) -- Radix, a global technology solutions company, announced its participation as a Sapphire sponsor at TAPPICon ...
Read morePhase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous ...
Read moreBOSTON, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Balt, Inc., a global technology leader in neurovascular devices, today announced the presentation ...
Read moreThe confirmatory clinical, safety and efficacy study for AVT06, biosimilar candidate to Eylea® (aflibercept) met its primary endpoint in patients ...
Read moreBOSTON, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development ...
Read moreAnalysis from MonumenTAL-1 study showed patients with relapsed or refractory multiple myeloma treated with talquetamab were subsequently treated effectively with ...
Read moreSYFOVRE reduced nonsubfoveal GA lesion growth by over 40% (monthly) in Year 3 compared to projected sham in the GALE ...
Read moreAt Tanla, we have a defining purpose ‘Empower Consumers and Enable Companies’. We have always operated in a manner ...
Read more© 2015 - 2024 LifeCare News - LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283 - Lifecarenews.in.
© 2015 - 2024 LifeCare News - LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283 - Lifecarenews.in.